<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104765</url>
  </required_header>
  <id_info>
    <org_study_id>15435</org_study_id>
    <secondary_id>I5Q-MC-CGAE</secondary_id>
    <nct_id>NCT02104765</nct_id>
  </id_info>
  <brief_title>A Study of LY2951742 in Healthy Japanese and Caucasian Participants</brief_title>
  <official_title>A Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 Administered Subcutaneously to Japanese and Caucasian Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety of the study drug known as LY2951742
      in healthy Japanese and Caucasians. The study will also investigate how the body processes
      the drug and how the drug affects the body. The study is expected to last about 5 to 7
      months, depending on the arm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Screening through Day 197</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration of LY2951742</measure>
    <time_frame>Predose on Day 1 through Day 197</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Curve of LY2951742</measure>
    <time_frame>Predose on Day 1 through Day 197</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>LY2951742 Single Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 of LY2951742 given subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2951742 Single Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 of LY2951742 given subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2951742 Single Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 of LY2951742 given subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2951742 Single Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4 of LY2951742 given subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2951742 Multiple Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2951742 given subcutaneously once every 4 weeks for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Single Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Multiple Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given subcutaneously once every 4 weeks for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2951742</intervention_name>
    <description>Administered subcutaneously.</description>
    <arm_group_label>LY2951742 Single Dose 1</arm_group_label>
    <arm_group_label>LY2951742 Single Dose 2</arm_group_label>
    <arm_group_label>LY2951742 Single Dose 3</arm_group_label>
    <arm_group_label>LY2951742 Single Dose 4</arm_group_label>
    <arm_group_label>LY2951742 Multiple Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered subcutaneously.</description>
    <arm_group_label>Placebo Single Dose</arm_group_label>
    <arm_group_label>Placebo Multiple Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants are either Caucasian or first generation Japanese.

          -  Participants' body mass index (BMI) is between 18.0 and 35.0 kilogram per meter square
             (kg/ m^2).

        Exclusion Criteria:

          -  Participants are heavy caffeine drinkers defined by regular intake of more than 5 cups
             of coffee (or equivalent in xanthine containing beverages) per day, and/or are unable
             or unwilling to abide by caffeine restrictions as specified in the protocol.

          -  Participants are smoking within the previous 6 months.

          -  Participants have received treatment with biologic agents (such as monoclonal
             antibodies) within 3 months or 5 half-lives (whichever is longer) prior to dosing or
             have received a vaccination within 1 month.

          -  Participants have known allergies to LY2951742, related compounds or any components of
             the formulation, or history of significant atopy.

          -  Participants are allergies to either humanized monoclonal antibodies, diphenhydramine,
             epinephrine, or methylprednisolone.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

